Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
University of Michigan Rogel Cancer Center
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
University of Wisconsin, Madison
BeOne Medicines
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Children's Oncology Group
University of Michigan Rogel Cancer Center
Bristol-Myers Squibb
Radiation Therapy Oncology Group
University of California, San Francisco
Bristol-Myers Squibb
Rutgers, The State University of New Jersey
Shanghai Henlius Biotech
Incyte Corporation
Hoffmann-La Roche
Mayo Clinic
Children's Oncology Group
Hoffmann-La Roche
University of Washington
Hoffmann-La Roche
M.D. Anderson Cancer Center
Bristol-Myers Squibb
SWOG Cancer Research Network
Wake Forest University Health Sciences
Merck Sharp & Dohme LLC
NRG Oncology
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
G1 Therapeutics, Inc.
BeiGene
Hoffmann-La Roche
Merck Sharp & Dohme LLC
St. Jude Children's Research Hospital
BeiGene
University Health Network, Toronto
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
American Regent, Inc.
Merck Sharp & Dohme LLC